Legislation & Regulation

In the AMCP Legislative Days 2025 Booklet, learn about AMCP’s position on legislation impacting managed care pharmacy, how to talk to Members of Congress and their staff, and helpful tips for engaging in effective dialogue.

Access the AMCP Legislative Days 2025 Education Slides, to learn the terminology most associated with a Member of Congress and understand key advocacy vocabulary to help explain AMCP’s positions on the The Access to Prescription Digital Therapeutics Act of 2025 (H.R. 3288/S. 1702) The Medicaid VBPs for Patients (MVP) Act (S. 1637) and the Ensuring Community Access to Pharmacist Services Act (H.R. 3164)

On May 22, 2025, the President’s Make America Healthy Again Commission published the MAHA report. The report raises concerns about the chronic childhood disease, processed food, environmental chemicals, lack of physical activity, mental health, and overmedicalization of American children.

On May 12, 2025, President Trump signed an Executive Order (EO) requiring agencies to take steps to encourage manufacturers to provide most-favored-nation pricing for prescription drugs.

On April 16, 2025, the Centers for Medicare and Medicaid Services (CMS) issued guidance on CY 2026 Part D Formulary Submissions (Guidance). The Guidance includes important dates related to CY 2026 formulary submissions.

On April 15, 2025, the Trump administration issued an Executive Order (EO) on prescription drug costs.

On April 7, 2025, the Centers for Medicare and Medicaid Services issued the Calendar Year (CY) 2026 Rate Announcement and Final CY 2026 Part D Redesign Program Instructions.